Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839911 | 1.00 | DRD2 (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL14157832 | 1.00 | DRD2 (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL873501 | 1.00 | DRD2 (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| Hydrochloric Acid SCHEMBL8823809 | 0.98 | DRD2 (0.53) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL9441617 | 0.81 | HTR1A (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL8886915 | 0.81 | HTR1A (0.54) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL4505997 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL14157823 | 0.78 | DRD2 (0.52) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL19054489 | 0.78 | HTR7 (0.38) | DRD2HTR1ADRD1HTR1BHTR2A | |
| SCHEMBL4749715 | 0.78 | HTR1B (0.44) | DRD2HTR1ADRD1HTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012039657-A1 | NOVEL CHROMANE COMPOUND FOR THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2012-03-29 | — | — | WO | disclosed |
| EP-1014986-B1 | A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1021183-B1 | A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1025096-B1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 2003-11-26 | — | — | EP | disclosed |
| EP-1014985-B1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A H5-HT 1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 2003-05-21 | — | — | EP | disclosed |
| US-6387899-B1 | ANTISEROTONINE AGENTS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2002-05-14 | — | — | US | disclosed |
| US-6384225-B1 | 5-PIPERIDINYL- OR PIPERAZINYL-SUBSTITUTED 3,4-DIHYDRO-2H-1-BENZOPYRANS | ASTRAZENECA AB (SE) | 2002-05-07 | — | — | US | disclosed |
| US-6159970-A | Combination of a monoamine oxidase inhibitor and a h5-HT1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6159972-A | Combination of a selective 5-HT1A antagonist and a selective ub. h5-HT.s1B antagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| US-6159971-A | Combination of a 5-HT reuptake inhibitor and a h5-HT1B anatagonist or partial agonist | ASTRAZENECA AB (SE) | 2000-12-12 | — | — | US | disclosed |
| EP-1025096-A1 | SUBSTITUTED CHROMAN DERIVATIVES | AstraZeneca AB (SE) | 2000-08-09 | — | — | EP | disclosed |
| EP-1014985-A1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT 1B ANTAGONIST OR PARTIAL AGONIST | AstraZeneca AB (SE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999014213-A1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
| WO-1999013877-A1 | A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |